Clinical trial
The Safety and Cost-effectiveness of Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS): a Randomized Rater-blinded Multicenter Trial.
NCT04260711 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Safety and Cost-effectiveness of Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS): a Randomized Rater-blinded Multicenter Trial.
- Lead sponsor
- Amsterdam UMC, location VUmc
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- July 1, 2020
- Completion date
- January 1, 2024
- Enrollment
- 130 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
multiple sclerosis, multiple sclerosis, relapsing-remitting, multiple sclerosis, secondary progressive